NUCLEAR MEDICINE AND BIOLOGY

Scope & Guideline

Advancing the frontiers of nuclear medicine and biology.

Introduction

Delve into the academic richness of NUCLEAR MEDICINE AND BIOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageMulti-Language
ISSN0969-8051
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1986 to 2024
AbbreviationNUCL MED BIOL / Nucl. Med. Biol.
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

The journal 'Nuclear Medicine and Biology' is dedicated to advancing the field of nuclear medicine through the publication of innovative research that focuses on the development, application, and evaluation of radiopharmaceuticals and imaging techniques. The journal encompasses a wide range of topics, including radiochemistry, molecular imaging, and targeted therapies, with an emphasis on both preclinical and clinical studies.
  1. Development of Radiopharmaceuticals:
    The journal emphasizes research on the synthesis, optimization, and characterization of radiopharmaceuticals, including novel agents for imaging and therapy.
  2. Molecular Imaging Techniques:
    There is a strong focus on the advancement of imaging modalities such as PET, SPECT, and hybrid imaging techniques, which are critical for diagnosing and monitoring diseases.
  3. Theranostics:
    The integration of diagnostic and therapeutic applications, particularly in the context of targeted radiotherapy and personalized medicine, is a core area of exploration.
  4. Radiochemistry Innovations:
    Research that explores new radiochemical methodologies, including novel labeling techniques and automation of synthesis processes, is a significant aspect of the journal.
  5. Preclinical and Clinical Applications:
    The journal publishes studies that bridge the gap between laboratory research and clinical applications, showcasing the translational potential of nuclear medicine.
  6. Biomarker Development:
    The identification and evaluation of biomarkers for various diseases, particularly cancer, through imaging and radiolabeled compounds are highlighted.
The journal 'Nuclear Medicine and Biology' has seen a significant evolution in its scope, with emerging themes reflecting advancements in technology and a shift towards personalized medicine. The following trends highlight the current focus areas within the journal.
  1. Targeted Alpha Therapy (TAT):
    There is a growing interest in targeted alpha therapy, reflecting advancements in the understanding of radiobiology and the therapeutic potential of alpha-emitting isotopes for cancer treatment.
  2. Artificial Intelligence in Imaging:
    The integration of artificial intelligence and machine learning techniques in imaging analysis and radiopharmaceutical development is rapidly emerging as a key focus area.
  3. Bioconjugation Techniques:
    Research on bioconjugation strategies for enhancing the delivery and efficacy of radiopharmaceuticals is trending, particularly in the context of antibody-drug conjugates.
  4. Immuno-PET Imaging:
    The application of PET imaging with immunoconjugates for monitoring immune responses and cancer therapies is increasingly prominent, reflecting the growing field of immuno-oncology.
  5. Nanoparticle-based Imaging and Therapy:
    The use of nanoparticles for targeted imaging and therapy is gaining traction, with studies focusing on their unique properties for enhancing drug delivery and imaging sensitivity.
  6. Radioligand Development for CNS Disorders:
    There is an emerging trend in developing radioligands specifically for imaging central nervous system disorders, reflecting the need for better diagnostic tools in neurology.

Declining or Waning

While 'Nuclear Medicine and Biology' continues to thrive in many areas, certain research themes have seen a decline in focus over recent years. This may indicate a shift in priorities within the field or the emergence of new methodologies and technologies.
  1. Traditional Radiopharmaceuticals:
    There is a noticeable decline in studies focused on traditional radiopharmaceuticals, as newer, more targeted agents and approaches gain popularity.
  2. Non-targeted Imaging Approaches:
    Research on non-targeted imaging methods appears to be waning, as the field increasingly emphasizes precision medicine and targeted imaging agents.
  3. Basic Radiochemistry:
    Papers focusing exclusively on basic radiochemistry without applications in imaging or therapy are becoming less frequent, reflecting a trend towards more applied research.
  4. Conventional SPECT Imaging:
    The prevalence of conventional SPECT imaging studies has decreased, possibly due to the increasing adoption of PET and hybrid imaging techniques that offer higher sensitivity and resolution.
  5. Invasive Procedures in Imaging:
    Research involving invasive imaging procedures has diminished as the focus shifts towards less invasive and more patient-friendly imaging technologies.

Similar Journals

BMC MEDICAL IMAGING

Empowering Researchers and Clinicians in Medical Imaging.
Publisher: BMCISSN: 1471-2342Frequency: 1 issue/year

BMC Medical Imaging is a premier open-access journal dedicated to advancing the field of radiology, nuclear medicine, and imaging technologies. Published by BMC in the United Kingdom, this journal serves as a vital resource for researchers, clinicians, and students, fostering a collaborative environment for sharing innovative findings and methodologies in medical imaging. With a commendable impact factor and an impressive Scopus ranking within the top 35% of its category, BMC Medical Imaging provides a platform for high-quality research to be disseminated widely and freely since its inception in 2001. The journal aims to cover a diverse array of topics, from advanced imaging techniques to their clinical applications, enhancing the understanding and effectiveness of diagnostic practices. By contributing to the body of knowledge and facilitating open access to research, BMC Medical Imaging plays a pivotal role in shaping the future of medical imaging and improving patient care.

Molecular Imaging

Exploring New Dimensions in Molecular Medicine.
Publisher: SAGE PUBLICATIONS INCISSN: Frequency: 1 issue/year

Molecular Imaging is a prominent journal published by SAGE Publications Inc., which serves as a vital platform for the dissemination of high-quality research in the field of molecular imaging. With an E-ISSN of 1536-0121, this journal has established itself within several key areas, including Biomedical Engineering, Biotechnology, Condensed Matter Physics, Molecular Medicine, and Radiology, Nuclear Medicine and Imaging. Spanning from 2002 to 2024 and currently classified within the prestigious Q2 and Q3 quartiles, Molecular Imaging aims to highlight the latest developments and innovative methodologies in molecular imaging techniques and applications. Researchers from diverse backgrounds will find the journal's content valuable for staying updated with recent advancements, evidenced by its competitive Scopus ranking and a commitment to fostering interdisciplinary collaboration. Although the journal is not open access, the rigorous peer-review process ensures that all published articles provide significant contributions to the field, making it an essential resource for professionals, researchers, and students alike.

NUKLEARMEDIZIN-NUCLEAR MEDICINE

Transforming Healthcare through Nuclear Medicine Discoveries.
Publisher: GEORG THIEME VERLAG KGISSN: 0029-5566Frequency: 6 issues/year

NUKLEARMEDIZIN-NUCLEAR MEDICINE is a prestigious journal published by Georg Thieme Verlag KG, focusing on pivotal advancements in the fields of Nuclear Medicine, Radiology, and Imaging. Established in 1959, this journal has served as a critical platform for disseminating innovative research, reviews, and clinical guidelines until its anticipated convergence in 2024. With an ISSN of 0029-5566 and an E-ISSN of 2567-6407, NUKLEARMEDIZIN is acknowledged in the academic community as a Q3 category journal within Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging as of 2023, highlighting its ongoing contribution to the interdisciplinary dialogue in healthcare. Although the journal does not currently offer open access, it remains accessible to professionals and students through various academic databases, ensuring that cutting-edge knowledge in this growing field is shared widely. Researchers interested in the latest methods and technologies in Nuclear Medicine will find NUKLEARMEDIZIN a valuable resource for enhancing their work and understanding the complexities of modern imaging modalities.

Molecular Imaging and Radionuclide Therapy

Advancing breakthroughs in molecular imaging and therapy.
Publisher: GALENOS PUBL HOUSEISSN: 2146-1414Frequency: 3 issues/year

Molecular Imaging and Radionuclide Therapy is an esteemed academic journal published by GALENOS PUBL HOUSE, dedicated to advancing the fields of radiology, nuclear medicine, and imaging. Since its inception, this Open Access journal has facilitated the dissemination of high-quality research and innovative practices in molecular imaging and radionuclide therapy, making it a vital resource for researchers, professionals, and students alike. With an ISSN of 2146-1414 and an E-ISSN of 2147-1959, the journal has established its presence globally while specifically catering to the Turkish academic and medical community. As of 2023, it is ranked #241/333 in the Radiology, Nuclear Medicine and Imaging category on Scopus, holding a respectable Q3 quartile ranking. The journal serves as a platform for sharing impactful findings from 2017 to 2024, reinforcing its commitment to open access since 2011. With a dedication to enhancing the knowledge base in molecular imaging and therapy, it remains an important conduit for scholarly communication and collaborative research developments in this dynamic field.

Clinical Imaging

Pioneering Discoveries in Radiology and Nuclear Medicine
Publisher: ELSEVIER SCIENCE INCISSN: 0899-7071Frequency: 6 issues/year

Clinical Imaging, published by Elsevier Science Inc, is a renowned journal dedicated to the field of radiology, nuclear medicine, and imaging. With an ISSN of 0899-7071 and an E-ISSN of 1873-4499, this esteemed publication has established its significance in advancing imaging science since its inception in 1989 and continues to make impactful contributions to the discipline through 2024. The journal holds a prestigious Q2 ranking in the category of Radiology, Nuclear Medicine, and Imaging, reflecting its critical role in bridging research and clinical practice. Currently ranked #113 out of 333 by Scopus, with a notable 66th percentile, it offers a platform for disseminating high-quality research, reviews, and case studies that inspire innovation and enhance imaging techniques. Although it primarily functions as a subscription-based journal, it remains dedicated to accessibility and the dissemination of pivotal findings that inform both academia and clinical settings. Clinical Imaging is essential for researchers, professionals, and students alike, offering insights that shape the future of diagnostic imaging.

Translational Cancer Research

Fostering collaboration for a cancer-free future.
Publisher: AME PUBLISHING COMPANYISSN: 2218-676XFrequency: 12 issues/year

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

NUCLEAR MEDICINE COMMUNICATIONS

Elevating Standards in Diagnostics and Therapeutics
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0143-3636Frequency: 12 issues/year

NUCLEAR MEDICINE COMMUNICATIONS is a prestigious academic journal published by Lippincott Williams & Wilkins, focusing on the multifaceted field of nuclear medicine and its applications in diagnostics and therapy. With a solid history spanning from 1980 to 2024, this journal provides a platform for peer-reviewed research articles, clinical studies, and innovative techniques that enrich the knowledge base within the fields of {{medicinal applications, patient care, and imaging technology}}. Currently classified in the Q3 quartile for both Medicine (Miscellaneous) and Radiology, Nuclear Medicine, and Imaging, the journal reflects its commitment to advancing healthcare practices. Although it does not offer open access options, its accessibility through reputable institutions promotes scholarly exchange among researchers, professionals, and students alike. The critical insights provided in NUCLEAR MEDICINE COMMUNICATIONS are essential for those dedicated to enhancing patient outcomes through cutting-edge nuclear medical technologies.

Revista Espanola de Medicina Nuclear e Imagen Molecular

Advancing the Frontiers of Nuclear Medicine and Molecular Imaging
Publisher: ELSEVIER ESPANA SLUISSN: 2253-654XFrequency: 6 issues/year

Revista Española de Medicina Nuclear e Imagen Molecular, published by Elsevier España SLU, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Molecular Imaging. With an ISSN of 2253-654X, this journal is committed to disseminating high-quality research and advancements in clinical practices, aiming to bridge the gap between theoretical research and application in healthcare. Operating since 2012, it features a robust archive of peer-reviewed articles and case studies, although it currently holds a Q4 ranking in the Scopus category, indicating significant potential for growth and influence within the academic community. The journal is indexed in Scopus, with a rank of 255 out of 333, placing it in the 23rd percentile, which underlines the need for increased contributions from researchers eager to enhance its standing. While it is not an open-access journal, its availability through libraries and institutions ensures that a wide audience can access critical findings and innovations in the rapidly evolving field of nuclear medicine. As we look towards the convergence period from 2012 to 2024, Revista Española de Medicina Nuclear e Imagen Molecular aspires to fortify its role as a cornerstone for collaboration and advancement in nuclear imaging and radiology.

PET Clinics

Pioneering Progress in Positron Emission Tomography.
Publisher: ELSEVIER INCISSN: 1556-8598Frequency: 4 issues/year

PET Clinics, published by Elsevier Inc, is a premier academic journal focusing on the advancements and applications of Positron Emission Tomography (PET) in various medical fields. With its ISSN 1556-8598 and E-ISSN 1559-7814, the journal has established a strong reputation in the scientific community, reflected in its impressive Q1 quartile rankings in Medicine (miscellaneous), Radiation, and Radiology, Nuclear Medicine, and Imaging for 2023. The journal operates within a well-defined scope that bridges innovative research and practical clinical applications, targeting professionals, researchers, and students keen on the intersection of nuclear medicine and imaging technologies. Although not an open-access journal, PET Clinics ensures accessibility through institutional subscriptions, making valuable insights available to the academic community. With an emphasis on enhancing patient care and treatment outcomes through cutting-edge imaging techniques, this journal serves as an essential resource for those seeking to expand their knowledge and expertise in the rapidly evolving field of PET.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Connecting Researchers to Transformative Medical Insights
Publisher: SPRINGERISSN: 1619-7070Frequency: 12 issues/year

The European Journal of Nuclear Medicine and Molecular Imaging is a prestigious, peer-reviewed journal published by Springer, dedicated to advancing the field of nuclear medicine and molecular imaging. With an impressive impact factor and ranked in the Q1 category for both Medicine and Radiology, Nuclear Medicine and Imaging, this journal is a pivotal platform for researchers and practitioners to disseminate significant findings from 1996 to the present, reflecting the evolution of the field. The journal boasts a notable Scopus rank, standing at #8 out of 333 in its category, placing it in the top 3% of published works, which highlights its critical importance in shaping contemporary practices and research innovations. Although it does not offer an open-access model, the journal provides various access options to ensure that important research is accessible to professionals, students, and academics alike. Through rigorous peer review and a commitment to high-quality publication, the European Journal of Nuclear Medicine and Molecular Imaging plays an essential role in the advancement of nuclear medicine, contributing to better diagnostic and therapeutic outcomes globally.